Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Share-based Compensation (2020 - 2025)

LifeStance Health (LFST) has disclosed Share-based Compensation for 6 consecutive years, with $16.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 3.46% to $16.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $74.7 million, a 1.93% decrease, with the full-year FY2025 number at $74.7 million, down 1.93% from a year prior.
  • Share-based Compensation was $16.7 million for Q4 2025 at LifeStance Health, down from $18.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $108.6 million in Q4 2021 to a low of $605000.0 in Q1 2021.
  • A 5-year average of $30.4 million and a median of $21.3 million in 2023 define the central range for Share-based Compensation.
  • Biggest YoY gain for Share-based Compensation was 9793.39% in 2022; the steepest drop was 67.6% in 2022.
  • LifeStance Health's Share-based Compensation stood at $108.6 million in 2021, then plummeted by 67.6% to $35.2 million in 2022, then tumbled by 40.56% to $20.9 million in 2023, then decreased by 22.82% to $16.1 million in 2024, then grew by 3.46% to $16.7 million in 2025.
  • Per Business Quant, the three most recent readings for LFST's Share-based Compensation are $16.7 million (Q4 2025), $18.3 million (Q3 2025), and $21.1 million (Q2 2025).